Houston cancer-fighting biotech company introduces its 4th ongoing clinical trial

health report

Houston-based Moleculin Biotech now has four different oncology treatment currently in trials. Getty Images

A Houston-based biotech company has wrapped up enrollment for its most recent clinical trial of its cancer-fighting drug.

Moleculin Biotech Inc. (Nasdaq: MBRX) has launched its fourth ongoing trial — this time focusing on Cutaneous T-Cell Lymphoma, or CTCL, treatment. The company's other three trials include treatment for glioblastoma, an aggressive brain cancer, pancreatic cancer, one of the most virulent killers in oncology, and acute myeloid leukemia, or AML.

To treat these various types of cancers, Moleculin has a several drugs it's in preclinical or clinical trials testing — most biotech companies have only one they focus on. WP1220 is the drug that will be used in this trial for topical CTCL treatment of the cancer's resulting skin lesions.

"We believe there continues to be an unmet need for an improved topical therapy for Stage I-III CTCL skin lesions," says Walter Klemp, Moleculin's chairman and CEO, in a news release, "especially one that may avoid significant unwanted side effects."

WP1220 is what's known as a p-STAT3 inhibitor. STAT3 is a transcription factor that encourages tumor development. Moleculin's technology directly attacks the tumor, but also quiets T Cells, which allows the body's own immune system to fight the cancer itself. Essentially, it works both as chemotherapy and immunotherapy.

"This proof of concept, if successful, could be an important first demonstration of a therapeutic effect in humans from such a p-STAT3 inhibitor," Klemp continues. "We are pleased with how quickly this trial reached full recruitment and we are hopeful to be able to announce results from this trial yet this year."

Klemp founded the company in 2007, and Moleculin went public in 2016. Now, with the company's four clinical trials, Moleculin is even closer to saving lives with its products.

"Notwithstanding the relatively rare nature of CTCL, we believe showing activity with one of our STAT3 inhibitors, within our WP1066 family of molecules, could be an indicator of both the value of p-STAT3 as a target and the potential for our drugs in other cancers where STAT3 is highly activated," Klemp says in the release.

With the Texas Medical Center in their backyard, these Houston biotech companies are creating breakthrough technologies. Getty Images

5 Houston biotech companies taking health care to new levels

The future is now

Houston is the home of the largest medical center in the world, so it comes as no surprise that the Bayou City is also home to breakthrough technologies. Here are five Houston companies developing some of this biotech advancements.

Moleculin Biotech Inc.

Houston-based Moleculin has three different oncology technologies currently in trials. Getty Images

Immunotherapy and personalized medicine get all the headlines lately, but in the fight against cancer, a natural compound created by bees could beat them in winning one battle.

In 2007, chairman and CEO Walter Klemp founded Moleculin Biotech Inc. as a private company. The former CPA had found success in life sciences with a company that sold devices for the treatment of acne. That introduction into the field of medical technology pushed him toward more profound issues than spotty skin.

"Coincidentally, the inventor of that technology had a brother who was a neuro-oncologist at MD Anderson," Klemp recalls.

The since-deceased Dr. Charles Conrad slowly lured Klemp into what he calls the "cancer ecosphere" of MD Anderson. In 2016, the company went public. And it looks like sooner rather than later, it could make major inroads against some of the toughest cancers to beat. Read the full story here.

Cavu Biotherapies

Dr. Colleen O'Connor has adapted immunotherapy treatments to be used in dogs. Courtesy of CAVU Biotherapies

Breakthrough biotech doesn't have to just be for humans. More than three years after its founding, Houston-based veterinary biotech company CAVU Biotherapies' had its first cancer patient: a black Labrador in Pennsylvania diagnosed with B-cell lymphoma.

Dr. Colleen O'Connor, CEO and founder of CAVU Biotherapies, established the company in July 2015 with a goal to help pets live longer post-cancer diagnoses. O'Connor, who earned a PhD in toxicology with a specialty in immunology, has more than a decade of hands-on experience researching cancer treatments.

"Our goal is to scale up and be able to increase our dogs' qualities of life with us," O'Connor said. "We want to keep families intact longer and we want to be able to modernize cancer care for our animals." Read the full story here.

Innovative Biochips

iBiochips, led by founder Lidong Qin, was awarded a $1.5 million grant in September to help develop a new technology that delivers data about the cell's genetic makeup and reports abnormalities. Courtesy of Lidong Qin

Innovative Biochips, a Houston-based biotechnology company, is one step closer to commercializing technology that the company hopes will provide an opportunity for researchers to detect diseases earlier.

The company was founded three years ago by Dr. Lidong Qin, a professor at the Houston Methodist Research Institute's department of nanomedicine. He launched iBiochips as an independent faculty startup that licensed technology from Houston Methodist. Qin says he wanted to engineer and manufacture devices that focus on revolutionizing single-cell isolation and genetic analysis. Read the full story here.

Celltex

Celltex's stem cell technology has received positive results from its multiple sclerosis, Parkinson's, and rheumatoid arthritis patients. Courtesy of Celltex

A Houston stem cell company is making strides in regenerative medicine. Celltex's treatment has been proved effective with its patients. Eighty-three percent of multiple sclerosis patients have reported improvement of symptoms specific to their disease, as have 73 percent of Parkinson's sufferers. But the staggering fact is that 100 percent of 58 respondents with rheumatoid arthritis say they have benefited.

David Eller, chairman, co-founder and CEO of the company, also recently announced the company's expansion to Saudi Arabia. Read the full story here.

Ridgeline Therapeutics

Houston-based Ridgeline Therapeutics isn't going to allow you beat aging, but someday it may well help you to live without muscle loss or diabetes. Getty Images

Stan Watowich pictures a world where elderly people have the same healthy muscles they had at a younger age. Watowich is CEO of Ridgeline Therapeutics, a spin-off company of the University of Texas Medical Branch in Galveston where he is an associate professor of biochemistry and molecular biology, and he wants to make it clear that he is not going to cure aging.

"You and I are still going to get old," he says. "But we have our hopes that as we get old our muscles will stay healthy."

He's talking about the drug candidate, RLT-72484. It has been shown to reactivate muscle stem cells and regenerate skeletal muscle in aged laboratory mice. Read the full story here.

From cryotherapy and NASA-inspired fitness to startup funding and biotech, this week's innovators to know are raising the bar on health tech and innovation. Courtesy photos

4 health-focused Houston innovators to know this week

Who's who

This week's innovators to know are focused on health and wellness, from a Houston-based cryotherapy franchise to the person behind funding medical device and digital health startups. We couldn't narrow these folks down to the usual three, so here are the four Houston innovators to know as we start the last week in February.

Juliana Garaizar, director of the Texas Medical Center Venture Fund

Courtesy of TMC

Juliana Garaizar has worked all around the world, and her international contacts and venture capital experience has landed her at the heart of the Texas Medical Center leading the TMC Venture Fund.

"I think TMC wants to be positioned as a strong competitor to the East and West Coasts as a point of entry for companies coming to the United States, but also for technology and commercializations from hospitals," she tells InnovationMap. "The fact that I'm already very connected to other countries — not only from the funding side but also from the research side, is really helpful."

Garaizar has her hands full running the $25 million nonprofit fund that invests around $2 million a year. Recipients, which all have a connection to TMC either through the accelerator or workspaces, receive a range between $250,000 to $500,000, and can go up to $1 million in a deal, Garaizar says. She is focused on securing deal flow for the fund before growing it more.

"In the long term, we would like to raise a bigger fun, around $100 million fund," she says. "We would need to make sure we have our deal flow ready for that, and a big part of that would be international deal flow."

Walter Klemp, chairman and CEO of Moleculin

Courtesy of Moleculin

It's pretty concerning to Walter Klemp that, while Houston has the world's largest medical center, "the tragic irony" is that other cities have far more biotech money ready to be invested.

"The Third Coast is really starved for capital," he tells InnovationMap. "What drew me into this was I was one of the few entrepreneurs that lived here that knew the ropes in terms of tapping into East and West Coast capital structures and could make that connection for them."

In 2007, chairman and CEO Walter Klemp founded Moleculin Biotech Inc. as a private company. The company has three core technologies currently being tested with some success, but the most promising is called WP1066, which uses propolis, a compound of beeswax, sap and saliva that bees produce to seal small areas of their hives, as a base. The active compound both downregulates the STAT3, a long-time Holy Grail in the cancer research world, and directly attacking the tumor, but also quieting T Cells, which allows the body's own immune system to fight the cancer itself. Essentially, it works both as chemotherapy and immunotherapy.

Jay Sutaria, founder and lead trainer of Sutaria Training & Fitness

Courtesy of ST&F

Earthbound Houstonians have a chance to use NASA training equipment thanks to Jay Sutaria's company, Sutaria Training & Fitness.

"It's exclusive access to the equipment that is not available openly in Houston," Sutaria tells InnovationMap. "NASA is a reference for us to become better trainers."

Sutaria founded his company in 2011 while he was a student at the University of Houston, and the company now operates with two trainers. His clients include professional athletes such as D.J. Augustin (Orlando Magic, NBA); and Tim Frazier (New Orleans Pelicans, NBA), however, Sutaria and his team offer professional personal training services to any type of athlete.

Kyle Jones, COO of iCRYO

Courtesy of iCryo

Kyle Jones says he's always known he was destined for entrepreneurship, and when he came across the potential of cryotherapy while working at a physical therapist office, he knew it was a scalable business.

He opened his first location of iCRYO in League City in 2015. Now the company is

Jones says he used the location to work out the kinks of his business model, since he didn't really have much to model after. One thing that was most important to Jones, with his PT background, was safety of the patients. He cared about this more than making money, he says.

"I knew first and foremost the one thing that the cryotherapy space didn't have was a certification program, which is kind of terrifying to me," Jones tells InnovationMap. "Any therapy has some type of schooling or certification — massage therapy and acupuncture both have it. Cryotherapy even to date does not a certification to it."

Houston-based Moleculin has three different oncology technologies currently in trials. Getty Images

Houston biotech company aims to enhance oncology treatment of highly resistant cancers

Med tech

Immunotherapy and personalized medicine get all the headlines lately, but in the fight against cancer, a natural compound created by bees could beat them in winning one battle.

"Coincidentally, the inventor of that technology had a brother who was a neuro-oncologist at MD Anderson," Klemp recalls.

Klemp observed that while Houston has the world's largest medical center, "the tragic irony" is that other cities have far more biotech money ready to be invested.

"The Third Coast is really starved for capital," he says. "What drew me into this was I was one of the few entrepreneurs that lived here that knew the ropes in terms of tapping into East and West Coast capital structures and could make that connection for them."

The company has three core technologies currently being tested with some success, but the most promising is called WP1066, named for researcher Waldemar Priebe, "a rock star" in his native Poland, according to Klemp, who works at MD Anderson. Though Priebe came to the U.S. in the 1980s, he is still an adjunct professor at the University of Warsaw and conducts some of his trials in Poland because it's easier to get grant money there.

WP1066 uses propolis, a compound of beeswax, sap and saliva that bees produce to seal small areas of their hives, as a base. The molecular compound that Priebe discovered affects STAT3 (signal transducer and activator of transcription), a transcription factor that encourages tumor development. In short, the active compound in WP1066 both downregulates the STAT3, a long-time Holy Grail in the cancer research world, and directly attacking the tumor, but also quieting T Cells, which allows the body's own immune system to fight the cancer itself. Essentially, it works both as chemotherapy and immunotherapy.

WP1066 is demonstrating drug-like properties in trials at MD Anderson on glioblastoma, the aggressive brain cancer that recently took the life of the hospital's former president, John Mendelsohn, as well as John McCain and Beau Biden. It is also being tested against pancreatic cancer, one of the most virulent killers cancer doctors combat.

Priebe also created Annamycin, named for his oldest daughter, a first-line chemotherapy drug that fights Acute Myeloid Leukemia without the cardiotoxicity that can damage patients' hearts even as they beat their cancer.

WP1122 uses yet another mechanism to fight cancer.

"Most people don't know that morphine is essentially a modified version of heroin," Klemp explains.

The difference between the poppy-based drugs? Heroin can cross the blood-brain barrier. It's described as the dicetyl ester of morphine. WP1122 is the dicetyl ester of 2DG (2-Deoxyglucose), a glycolysis inhibitor, which works by overfilling tumor cells with fake glucose so that they can't consume the real glucose that makes them grow.

"The theory is, we could feed you so full of junk food that eventually you'd starve to death," Klemp elucidates. It can cross the blood-brain barrier and is metabolized slowly, meaning that it can be made into a drug in a way that 2DG cannot.

What's impressive about Moleculin is its diversity of drugs. Most companies have one drug that gets all or most of the attention. Moleculin has strong hopes for all three currently in trials.

"It's essentially multiple shots on the goal," says executive vice president and CFO Jonathan Foster.

Moleculin has 13 total employees, five of whom are based in Houston. An office in the Memorial Park area serves as a landing pad for employees and collaborators from around the world to get their work done when in Space City. The virtual office set-up works for the company because experts can stay in their home cities to get their work done. And that work is on its way to saving scores of lives.

Ad Placement 300x100

Ad Placement 300x600

CultureMap Emails are Awesome

Property Showcase

5 ways technology is transforming the workplace for people with disabilities

Guest Column

When Camp For All opened its barrier-free gates more than 30 years ago, our founders believed that design could level the playing field for children and adults with challenging illnesses, disabilities, or special needs. Today, that same philosophy is necessary for workplaces across Greater Houston and beyond; only now the ramps and handrails are digital as much as physical, powered by artificial intelligence (AI) and innovation.

Technology has significantly transformed the workplace for individuals with disabilities, making it easier for them to perform their roles with greater efficiency and independence. Tools such as ergonomic workstations, adaptive keyboards, closed captioning, dictation software, screen magnifiers, and robotics help customize the work environment to accommodate various needs. Additionally, advancements in remote work technology have opened the door to broader employment opportunities, reducing physical barriers to participation in the workforce.

Here are five ways that technology turns “reasonable accommodation” into universal enablement and why every employer should take note.

From closed-captioning to real-time conversation

Ten years ago, businesses relied upon human typists and translators to convert conversations and presentations for those with disabilities. Today, AI speech-to-text engines like Microsoft 365’s Live Captions or Google Workspace’s Meet Transcripts render spoken words into on-screen text across 40-plus languages and dialects in milliseconds. This means deaf and hard-of-hearing employees can follow rapid brainstorming sessions without waiting for a post-meeting transcript.

If you are not already using these tools in your workplace, it is easy to start. Most of these services are free or very low-cost, but produce a high return in employee productivity. Individuals with hearing deficiencies can participate in real-time conversations, give feedback, and bring their unique perspectives to the conversation. These tools also enhance productivity for the larger team by providing all employees with a greater flow of ideas, engagement, and recall.

Voice is the new keyboard

Voice assistants like Siri, Alexa, and Windows Voice Access have matured into integrated tools for everyday life and business. They can now handle paragraph-length dictation, code snippets, and complex spreadsheet commands.

Workers with limited dexterity or sight can participate fully in work tasks, which can level the playing field so everyone can succeed and contribute significantly to the workplace. Additionally, voice-assisted technology can help older employees or employees with differing physical needs continue working longer and retain vital organizational knowledge and expertise, contributing to their team's success.

Readability and writing coaches at scale

The new and highly sensitive AI-powered editors, such as GrammarlyGO and Microsoft Editor, flag jargon, suggest plain-language rewrites, and even adjust tone for cognitive accessibility. This can be a game-changer for neurodivergent professionals, including people with dyslexia or ADHD, as they have to use less brain power decoding dense emails and can get help writing responses in their workplace correspondence.

Again, these free or low-cost tools enable all team members to contribute their unique ideas and perspectives when working together to address workplace challenges, better serve clients, and increase productivity.

Alternative text that captures context

Image-recognition models can now draft alt-text beyond “blue shirt on chair.” Tools like Adobe’s Intelligent Captioning or Meta’s Automatic Alt Text describe emotion, action, and even brand context, giving screen-reader users a richer experience.

Employees with blindness or low vision are more likely to navigate online documents, presentations, and requests independently. These technologies also reduce workloads on marketing teams and help them meet accessibility standards without extensive labor and time.

For businesses that want a varied workforce that brings multiple perspectives, these tools give them a power that hasn’t been harnessed before. If employees living with disabilities have more tools at their disposal, they can, in turn, target specific customers in new ways.

Robots and exoskeletons

Many of us remember The Jetsons cartoon show from the 1960s and how far-fetched their housekeeper robot Rosie seemed then. But now, affordable robots and wearable devices to support employees with spinal cord injuries, chronic pain, and disabilities are helping perform repetitive tasks and reducing strain for everyday work tasks.

These devices may revolutionize unemployment to full-time employment opportunities for many individuals. Devices like ABB’s GoFa and Ottobock’s Paexo can help employers reduce injury claims and retain skilled staff; it’s truly a win-win for employees and employers.

The impact is universal

Eight-foot-wide accessible sidewalks, like the ones we have at Camp For All, help wheelchair users, parents pushing a stroller, and travelers rolling luggage. Similarly, AI captions level the playing field for hearing-impaired colleagues, neurodiverse team members, aging professionals, and every employee skimming a meeting on mute. When we treat accessibility as an innovation driver rather than a compliance checklist, we unleash the potential of productivity, loyalty, and creativity throughout our organizations and companies.

Camp For All sees this throughout the year: when design removes barriers, people discover abilities they never knew they had. Let’s bring that spirit into every Houston boardroom and breakroom — because an inclusive workplace isn’t just the right thing, it’s the smart thing.

---

Pat Prior Sorrells is president and CEO of Camp For All, a Texas-based nonprofit organization. Located in Burton, Texas, the 206-acre Camp For Allsite was designed with no barriers for children and adults with special needs to experience the joy of camping and nature. Camp For All collaborates with more than 65 nonprofit organizations across the Greater Houston area and beyond to enable thousands of campers and their families to discover life each year. She speaks regularly on the need for inclusive design in public spaces.

CPRIT grants $22M to bring top cancer researchers to Houston

fresh funding

Several prominent cancer researchers are coming to the Houston area thanks to $22 million in grants recently awarded by the Cancer Prevention and Research Institute of Texas (CPRIT).

The biggest CPRIT recruitment grant — $6 million — went to genetics researcher Jean Gautier. Gautier, a professor of genetics and development at Columbia University’s Institute for Cancer Genetics, is joining the University of Texas MD Anderson Cancer Center to continue his research.

The website for Gautier’s lab at Columbia provides this explanation of his research:

“The main objective of our research is to better understand the molecular mechanisms responsible for the maintenance of genome stability. These controls are lost in cancer, which is characterized by genomic instability.”

Aside from his work as a professor, Gautier is co-leader of the Herbert Irving Comprehensive Cancer Center’s Cancer Genomics and Epigenomics Program at Columbia.

Other recipients of CPRIT recruitment grants include:

$2 million to recruit Xun Sun from the Scripps Research Institute to the University of Texas Medical Branch at Galveston.
$2 million to recruit Mingqi Han from the University of California, Los Angeles to MD Anderson.
$2 million to recruit Matthew Jones from Stanford University to MD Anderson.
$2 million to recruit Linna An from the University of Washington to Rice University.
$2 million to recruit Alissa Greenwald from the Weizmann Institute of Science to MD Anderson.
$2 million to recruit Niladri Sinha from Johns Hopkins University to the Baylor College of Medicine.
$2 million for Luigi Perelli to stay at MD Anderson so he can be put on a tenure track and set up a research lab.
$2 million for Benjamin Schrank to stay at MD Anderson so he can be put on a tenure track and set up a research lab.

Over $20.2 million in academic research grants were awarded to researchers at:

Baylor College of Medicine
Houston Methodist Research Institute
Rice University
Texas Southern University
University of Houston
University of Texas Health Science Center at Houston
University of Texas MD Anderson Cancer Center
University of Texas Medical Branch at Galveston

In addition, nearly $4.45 million in cancer prevention grants were awarded to one researcher at the University of Texas Medical Branch at Galveston and another at Texas Southern University.

Also, five Houston businesses benefited from CPRIT grants for product development research:

Allterum Therapeutics, $2,999,996
CTMC, $1,342,178
Instapath, $900,000
Prana Surgical, $900,000
InformAI, $465,188

“Texas is a national leader in the fight against cancer,” said Kristen Pauling Doyle, CPRIT’s CEO. “We can measure the return on investment from CPRIT grants … not only in the economic benefits flowing from increased financial activity and jobs in the state, but more importantly in the cancers avoided, detected early, and treated successfully. Thanks to the Legislature’s vision, this commitment is saving lives.”

Overall, CPRIT approved 61 grants totaling more than $93 million in this recent round of funding.

The Houston app that makes your commute smoother, greener + more rewarding

Return to Office

As Houstonians transition back to the office, navigating the city’s complex traffic landscape can feel overwhelming. Fortunately, Houston ConnectSmart, a free app designed specifically for the greater Houston area, is here to make that return easier on your schedule, your wallet, and even the planet.

Unlike national navigation apps, ConnectSmart is built with local commuters in mind. It offers features tailored to Houston’s unique traffic patterns, such as real-time alerts about road closures, construction zones, and flooding. The app also integrates live traffic camera feeds and notifies users about adverse weather conditions, helping them adjust their routes efficiently and avoid delays.

ConnectSmart goes beyond basic navigation. It’s the only local app that keeps commuters fully informed with proactive, real-time trip alerts. These alerts tell users exactly when to leave, flag incidents on their routes, and provide alternative paths to ensure the smoothest possible drive. Additionally, through the Tow and Go program, users stranded on eligible freeways can access no-cost towing to a safe location.

For those looking to save money, time, and the planet, ConnectSmart also shines as a carpooling tool.

With its Carpool feature, users can coordinate rides with colleagues or friends, making use of HOV lanes and cutting down on the number of single-occupancy vehicles on the road. Whether you're a driver or a rider, the app allows you to customize your commute by setting pick-up points, schedules, and drop-off locations. If plans change, Trip Protection ensures you won’t be stranded, offering compensation for a backup ride home in the event of a last-minute cancellation.

Carpooling with ConnectSmart doesn’t just ease stress — it also lightens your environmental footprint and reduces the wear and tear on your vehicle. The app even provides real-time parking information for garages, lots, and street spaces, making the end of your commute as hassle-free as the journey itself.

For employers, ConnectSmart offers an Employer Commute Suite that enables organizations to set up private carpool groups for staff. This feature fosters a more connected, sustainable workplace culture and helps businesses support employees in managing their daily commutes.

Whether you're driving solo or looking to share a ride, Houston ConnectSmart brings a smarter, more sustainable way to get around the Bayou City. Download the app for free from the App Store or Google Play, and start your commute with confidence, convenience, and community in mind.

For more information about setting up an Employer Commute Suite, contact ConnectSmart today and take the first step toward transforming how your organization gets to work.

View All Listings

INNOVATIONMAP EMAILS ARE AWESOME